Corcept Therapeutics Incorporated (FRA:HTD)

Germany flag Germany · Delayed Price · Currency is EUR
71.12
-0.74 (-1.03%)
Last updated: Dec 4, 2025, 8:00 AM CET
26.46%
Market Cap 7.79B
Revenue (ttm) 631.70M
Net Income (ttm) 89.20M
Shares Out n/a
EPS (ttm) 0.74
PE Ratio 87.28
Forward PE 73.76
Dividend n/a
Ex-Dividend Date n/a
Volume 400
Average Volume 20
Open 71.12
Previous Close 71.86
Day's Range 71.12 - 71.12
52-Week Range 48.28 - 105.30
Beta n/a
RSI 61.43
Earnings Date Feb 18, 2026

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 500
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol HTD
Full Company Profile

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Financial numbers in USD Financial Statements

News

There is no news available yet.